New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
• By PharmAsia News
CAMBRIDGE, Mass. - Life science companies looking to provide healthcare solutions to the poorer, "bottom of the pyramid" - a population reaching more than 600 million people in India alone - should focus on business model innovation as much as on innovative products, according to delegates at the U.S.-India Chamber of Commerce biopharmaceutical and healthcare summit in Cambridge, Mass
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline
Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.